Opus Genetics to Showcase Innovative Therapies at Conference

Opus Genetics Set to Engage at H.C. Wainwright Conference

Opus Genetics, Inc. (Nasdaq: IRD), a cutting-edge clinical-stage biopharmaceutical company, is excited to announce its participation at the prestigious H.C. Wainwright 27th Annual Global Investment Conference. Scheduled for September 8-10, 2025, this event represents an opportunity for the company to provide an insightful update about its ongoing progress in developing transformative gene therapies.

Spotlight on Innovative Presentations

George Magrath, MD, the Chief Executive Officer of Opus Genetics, along with Ash Jayagopal, Ph.D., MBA, the Chief Scientific and Development Officer, will present a corporate update that highlights significant advancements and future directions. The presentation will be available on demand starting September 8, 2025, at 7:00 a.m. ET, allowing investors and stakeholders to stay informed about the company’s trajectory.

Recent Investor Engagements

In addition to the upcoming conference, Opus Genetics has provision for replays from other recent investor engagements. These include:

• Nasdaq Spotlight interview
• Chardan Virtual Ophthalmology Summit Series, featuring discussions on rare ophthalmic diseases
• Jones Trading's Virtual Presbyopia Expert Panel

Accessing Replay Opportunities

Interested parties can find access to these webcasts under the Investor section of the Opus Genetics website. Engaging with these materials can provide valuable insights into the company's strategy and developments in the field of ophthalmology.

Unpacking the Mission of Opus Genetics

At its core, Opus Genetics is dedicated to tackling inherited retinal diseases (IRDs) through groundbreaking innovations. Their pipeline bravery features AAV-based gene therapies specifically aimed at addressing critical conditions like Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. These conditions make everyday activities challenging for those affected, and the therapies developed by Opus Genetics promise to change lives.

Leading the Charge

The lead gene therapy candidates of Opus Genetics include OPGx-LCA5, currently undergoing an ongoing Phase 1/2 trial targeting LCA5-related mutations. Additionally, they are advancing OPGx-BEST1, which is engineered to tackle BEST1-related retinal degeneration. These innovative solutions are on the forefront of genetic medicine in ophthalmology.

Expanding Treatment Horizons

Moreover, Opus Genetics is also making strides in the development of Phentolamine Ophthalmic Solution 0.75%. This partnered therapy is already approved for certain indications and is currently undergoing two Phase 3 programs aimed at addressing presbyopia, as well as enhancing visual function in low light and nighttime conditions. The potential impact of these advancements on individuals' lives cannot be overstated.

Commitment to Excellence

Based in Research Triangle Park, NC, Opus Genetics remains committed to providing innovative solutions for ophthalmic disorders. Their work not only represents scientific progress but also the hope for those who struggle with these debilitating conditions. For any further information, including details about ongoing trials and the corporate strategy, you can visit the official Opus Genetics website.

Frequently Asked Questions

What is Opus Genetics focusing on at the conference?

Opus Genetics will present a corporate update about their advancements in gene therapies for inherited retinal diseases.

When is the presentation available for viewing?

The presentation will be available on demand on September 8, 2025, at 7:00 a.m. ET.

What are some recent programs by Opus Genetics?

Recent programs include the Nasdaq Spotlight interview and discussions on rare ophthalmic diseases in virtual summits.

What are the main therapies being developed by Opus Genetics?

Opus Genetics is developing gene therapies targeting LCA, bestrophinopathy, retinitis pigmentosa, and a treatment for presbyopia.

Where is Opus Genetics located?

The company is based in Research Triangle Park, North Carolina.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.